Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2021 Financial Results
04 nov. 2021 16h05 HE
|
Longboard Pharmaceuticals, Inc.
Successfully completed multiple ascending dose (MAD) portion of a Phase 1 clinical trial for LP352, a potential treatment for seizures associated with a broad range of severe epilepsiesInitiating a...